EV/EBITDA Multiple: Zentalis Pharmaceuticals (ZNTL)

Graphic logo of Zentalis Pharmaceuticals Inc (ZNTL)

Zentalis Pharmaceuticals (ZNTL) is engaged in an intensive scientific and technical struggle to create effective small molecules. This historical EV/EBITDA chart currently stands at 0.00. The business relies on the development of precision therapies for breast and ovarian tumors tailored for oncology centers. The scaling model is based on intellectual property protection, enabling the global distribution of innovative drugs with high margins.

ZNTL Zentalis Pharmaceuticals, Inc.: Enterprise Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/17/2026

ZNTL (Zentalis Pharmaceuticals, Inc.): analytical breakdowns and indicator data

- current price and projected stock value:
- company stock exchange capitalization indicators:
Summary company analysis:Zentalis Pharmaceuticals Inc (ZNTL)
Product sample of Zentalis

Zentalis Pharmaceuticals (ZNTL) faces a complex balance between operational risks and return on capital due to the lack of stable revenue prior to the completion of Wee1 inhibitor trials. An analysis of the company's EV/EBITDA multiple on the GURU.Markets platform allows for a comparison of the total enterprise value, including debt, against its operating profitability, thereby determining the stability of the capital structure while awaiting drug commercialization.